Vancouver, Kelowna, and Delta, British Columbia–(Newsfile Corp. – December 18, 2024) – Investorideas.com, a global news source and expert investing resource covering AI stocks issues a snapshot for the sector looking at some of the top AI applications, featuring Avant Technologies, Inc. (OTCQB: AVAI), an emerging technology company developing solutions in artificial intelligence in healthcare.
Read the full article on Investorideas.com
https://www.investorideas.com/news/2024/technology/12180AI-Applications.asp
Statista.com says, “The market for artificial intelligence grew beyond 184 billion U.S. dollars in 2024, a considerable jump of nearly 50 billion compared to 2023. This staggering growth is expected to continue with the market racing past 826 billion U.S. dollars in 2030.”
AI is being integrated into almost every aspect of our daily lives and moving technology ahead at warp speed.
According to Simplilearn, “One of the critical AI applications is its integration with the healthcare and medical field. AI transforms healthcare by improving diagnostics, personalizing treatment plans, and optimizing patient care. AI algorithms can analyze medical images, predict disease outbreaks, and assist in drug discovery, enhancing the overall quality of healthcare services.”
Focusing on AI and healthcare, Avant Technologies Inc. (OTCQB: AVAI), and its partner, Ainnova Tech, Inc., a leading healthcare technology company focused on revolutionizing early disease detection using artificial intelligence (AI), just announced Ainnova’s acquisition of an exclusive license for four groundbreaking, AI-driven algorithms from one of Asia’s most respected and largest healthcare institutions. These solutions, validated across diverse geographies, ethnicities, and socioeconomic populations with data from over 2 million patients, will join Ainnova’s existing diabetic retinopathy and retinal disease detection solutions.
From the news: The four algorithms include early detection for cardiovascular risk, prediabetes and Type 2 diabetes, fatty liver disease and chronic kidney disease. Combined with Ainnova’s existing retinal disease detection tools, these new algorithms will be used with Ainnova’s powerful cutting-edge AI platform, VisionAI, to detect the early markers of these diseases quickly and accurately by applying AI.
Continued: The acquisition of an exclusive license to use four advanced algorithms in the Americas offers Ainnova Acquisition Corp. (AAC), the company formed by the partnership between Avant and Ainnova, a robust platform for primary care providers to streamline early risk screening and improve patient care in the United States.
